Definitions and mechanisms of drug hypersensitivity

Expert Review of Clinical Pharmacology

Volumn 3, Issue 4, 2010, Pages 539-551

  Wedi, Bettina ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

anaphylaxis; cutaneous adverse drug reaction; drug allergy; drug hypersensitivity; maculopapular rash; mechanism; urticaria

Indexed keywords

ALLOPURINOL; AMINOPENICILLIN; AMINOPHENAZONE; AMPICILLIN; BETA LACTAM ANTIBIOTIC; CARBAMAZEPINE; CLOZAPINE; COTRIMOXAZOLE; DILTIAZEM; HYDRALAZINE; LAMOTRIGINE; MACROLIDE; MINOCYCLINE; NEOMYCIN; NEVIRAPINE; OXICAM DERIVATIVE; PENICILLAMINE; PENICILLIN G; PHENOBARBITAL; PHENOTHIAZINE; PHENYTOIN; PROCAINAMIDE; QUINIDINE; QUININE; QUINOLONE; RIFAMPICIN; SALAZOSULFAPYRIDINE; SULFONAMIDE; TICLOPIDINE; UNINDEXED DRUG;

ACNE CONGLOBATA; ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; AGRANULOCYTOSIS; ANAPHYLACTIC SHOCK; ANGIONEUROTIC EDEMA; ANTIGEN ANTIBODY COMPLEX; ARTHRALGIA; AUTOIMMUNE DISEASE; BRONCHOSPASM; BULLOUS SKIN DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMORBIDITY; CONTACT DERMATITIS; CYTOPENIA; DISEASE PREDISPOSITION; DOSE RESPONSE; DRESS SYNDROME; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; ERYTHEMA; ERYTHEMA MULTIFORME; FEVER; FOLLICULITIS; GENETIC VARIABILITY; GRAFT VERSUS HOST REACTION; HEMOLYTIC ANEMIA; HEPATITIS; HEREDITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTENSION; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNE COMPLEX DISEASE; INFLAMMATORY INFILTRATE; LUPUS LIKE SYNDROME; MACULOPAPULAR RASH; MYOCARDITIS; NEPHRITIS; PANNICULITIS; PNEUMONIA; PROVOCATION TEST; PUSTULE; REVIEW; RISK ASSESSMENT; SHOCK; STEVENS JOHNSON SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH2 CELL; THROMBOCYTOPENIA; TREATMENT FAILURE; URTICARIA; VASCULITIS;

EID: 77954938802     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/ecp.10.32     Document Type: Review

References (95)

1. Aberer W, Bircher A, Romano A et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 58(9), 854-863 (2003).
2. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 356(9237), 1255-1259 (2000).
3. Pirmohamed M, James S, Meakin S et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329(7456), 15-19 (2004). (Pubitemid 38869995)
4. Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch. Intern. Med. 167(16), 1752-1759 (2007).
5. Aronson JK, Ferner RE. Joining the DoTS: new approach to classifiying adverse drug reactions. BMJ 327, 1222-1225 (2003).
6. Ferner RE, Aronson JK. EIDOS: a mechanistic classification of adverse drug effects. DrugSaf. 33(1), 1-8 (2010).
7. Johansson SG, Hourihane JO, Bousquet J et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy 56, 813-824 (2001).
8. Justiniano H, Berlingeri-Ramos AC, Sanchez JL. Pattern analysis of drug- induced skin diseases. Am. J. Dermatopathol. 30(4), 352-369 (2008).
9. Bousquet PJ, Kvedariene V, Co-Minh HB et al. Clinical presentation and time course in hypersensitivity reactions to p-lactams. Allergy 62(8), 872-876 (2007).
10. Blanca M, Romano A, Torres MJ et al. Update on the evaluation of hypersensitivity reactions to p lactams. Allergy 64(2), 183-193 (2009).
11. Torres MJ, Blanca M, Fernandez J et al. Diagnosis of immediate allergic reactions to beta-lactam antibiotics. Allergy 58(10), 961-972 (2003). (Pubitemid 37260337)
12. Schmid DA, Campi P, Pichler WJ. Hypersensitivity reactions to quinolones. Curr. Pharm. Des. 12(26), 3313-3326 (2006).
13. Manfredi M, Severino M, Testi S et al. Detection of specific IgE to quinolones. J. Allergy Clin. Immunol. 113(1), 155-160 (2004).
14. Heinzerling L, Raile K, Rochlitz H, Zuberbier T, Worm M. Insulin allergy: clinical manifestations and management strategies. Allergy 63(2), 148-155 (2008).
15. Jappe U. Allergy to heparins and anticoagulants with a similar pharmacological profile: an update. Blood Coagul. Fibrinolysis 17(8), 605-613 (2006).
16. Mertes PM, Imone-Gastin I, Gueant- Rodriguez RM et al. Hypersensitivity reactions to neuromuscular blocking agents. Curr. Pharm. Des. 14(27), 2809-2825 (2008).
17. Romano A, Blanca M, Torres MJ et al. Diagnosis of nonimmediate reactions to p-lactam-antibiotics. Allergy 59, 1153-1160 (2004).
18. Pichler WJ, Yawalkar N, Britschgi M et al. Cellular and molecular pathophysiology of cutaneous drug reactions. Am. J. Clin. Dermatol. 3(4), 229-238 (2002).
19. Pichler W, Yawalkar N, Schmid S, Helbling A. Pathogenesis of drug-induced exanthems. Allergy 57(10), 884-893 (2002).
20. Posadas SJ, Pichler WJ. Delayed drug hypersensitivity reactions - new concepts. Clin. Exp. Allergy 37(7), 989-999 (2007).
21. Matzinger P. The danger model: a renewed sense of self. Science 296(5566), 301-305 (2002).
22. Pirmohamed M, Naisbitt DJ, Gordon F, Park BK. The danger hypothesis - potential role in idiosyncratic drug reactions. Toxicology 181-182, 55-63 (2002).
23. Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann. Intern. Med. 146(9), 657-665 (2007).
24. Flanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. Hum. Psychopharmacol. 23(Suppl. 1), 27-41 (2008).
25. Williams DP, Kitteringham NR, Naisbitt DJ, Pirmohamed M, Smith DA, Park BK. Are chemically reactive metabolites responsible for adverse reactions to drugs? Curr. DrugMetab. 3(4), 351-366 (2002).
26. Gao Y, Zhao MH. Review article: drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrology (Carlton) 14(1), 33-41 (2009).
27. Wiik A. Drug-induced vasculitis. Curr. Opin. Rheumatol. 20(1), 35-39 (2008).
28. Merkel PA. Drug-induced vasculitis. Rheum. Dis. Clin. North Am. 27(4), 849-862 (2001).
29. Hari Y, Frutig-Schnyder K, Hurni M et al. T cell involvement in cutaneous drug eruptions. Clin. Exp. Allergy 31(9), 1398-1408 (2001).
30. Barbaud A. Drug patch tests in the investigation of cutaneous adverse drug reactions. Ann. Dermatol. Venereol. 136(8-9), 635-644 (2009).
31. Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxicology 209(2), 209-216 (2005).
32. Lochmatter P, Zawodniak A, Pichler WJ. In vitro tests in drug hypersensitivity diagnosis. Immunol. Allergy Clin. North Am. 29(3), 537-554 (2009).
33. Nyfeler B, Pichler WJ. The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity. Clin. Exp. Allergy 27(2), 175-181 (1997).
34. Martin M, Wurpts G, Ott H et al. In vitro detection and characterization of drug hypersensitivity using flow cytometry. Allergy 65(1), 32-39 (2009).
35. Zawodniak A, Lochmatter P, Yerly D et al. In vitro detection of cytotoxic T and NK cells in peripheral blood of patients with various drug-induced skin diseases. Allergy 65(3), 376-384 (2009).
36. Fernandez TD, Canto G, Blanca M. Molecular mechanisms of maculopapular exanthema. Curr. Opin. Infect. Dis. 22(3), 272-278 (2009).
37. Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J. Dtsch Dermatol. Ges. 7(2), 142-160 (2009).
38. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N. Engl. J. Med. 331(19), 1272-1285 (1994).
39. Letko E, Papaliodis DN, Papaliodis GN, Daoud YJ, Ahmed AR, Foster CS. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann. Allergy Asthma Immunol. 94(4), 419-436 (2005).
40. Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J. Am. Acad. Dermatol. 56(2), 181-200 (2007).
41. Carr DR, Houshmand E, Heffernan MP. Approach to the acute, generalized, blistering patient. Semin. Cutan. Med. Surg. 26(3), 139-146 (2007).
42. Levi N, Bastuji-Garin S, Mockenhaupt M et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics 123(2), E297-E304 (2009).
43. Struck MF, Hilbert P, Mockenhaupt M, Reichelt B, Steen M. Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes. Intensive Care Med. 36(1), 22-32 (2009).
44. Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J. Am. Acad. Dermatol. 58(1), 33-40 (2008).
45. Mockenhaupt M, Viboud C, Dunant A et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR- study. J. Invest. Dermatol. 128(1), 35-44 (2008).
46. Barreiro P, Soriano V, Casas E et al. Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids. AIDS 14(14), 2153-2157 (2000).
47. Halevy S, Ghislain PD, Mockenhaupt M et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J. Am. Acad. Dermatol. 58(1), 25-32 (2008).
48. Sachs B, Ronnau AC, Ruzicka T, Gleichmann E, Schuppe HC. Lamotrigine and toxic epidermal necrolysis. Lancet 348(9041), 1597 (1996).
49. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br. J. Dermatol. 68, 355-361 (1956).
50. Stanley JR, Amagai M. Pemphigus, bullous impetigo, and the staphylococcal scalded- skin syndrome. N. Engl. J. Med. 355(17), 1800-1810 (2006).
51. Correia O, Delgado L, Barbosa IL et al. CD8+ lymphocytes in the blister fluid of severe acute cutaneous graft-versus-host disease: further similarities with toxic epidermal necrolysis. Dermatology 203(3), 212-216 (2001).
52. Quinn AM, Brown K, Bonish BK et al. Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. Arch. Dermatol. 141(6), 683-687 (2005).
53. Correia O, Delgado L, Ramos JP, Resende C, Torrinha JA. Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement. Arch. Dermatol. 129(4), 466-468 (1993).
54. Nassif A, Bensussan A, Boumsell L et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J. Allergy Clin. Immunol. 114(5), 1209-1215 (2004).
55. Lonjou C, Thomas L, Borot N et al. A marker for Stevens-Johnson syndrome ethnicity matters. Pharmacogenomics J. 6(4), 265-268 (2006).
56. Lonjou C, Borot N, Sekula P et al. A European study of HLA-B in Stevens- Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet. Genomics 18(2), 99-107 (2008).
57. Hung SI, Chung WH, Liou LB et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl Acad. Sci. USA 102(11), 4134-4139 (2005).
58. Correia O, Delgado L, Roujeau JC, Le CL, Fleming-Torrinha JA. Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis: a comparative analysis of serum and blister fluid samples. Arch. Dermatol. 138(1), 29-32 (2002).
59. Wolkenstein P, Charue D, Laurent P, Revuz J, Roujeau JC, Bagot M. Metabolic predisposition to cutaneous adverse drug reactions. Role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants. Arch. Dermatol. 131(5), 544-551 (1995).
60. Miyauchi H, Hosokawa H, Akaeda T, Iba H, Asada Y. T-cell subsets in drug- induced toxic epidermal necrolysis. Possible pathogenic mechanism induced by CD8-positive T cells. Arch. Dermatol. 127(6), 851-855 (1991).
61. Viard I, Wehrli P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282, 490-493 (1998).
62. Abe R. Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases. J. Dermatol. Sci. 52(3), 151-159 (2008).
63. Murata J, Abe R, Shimizu H. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment. J. Allergy Clin. Immunol. 122(5), 992-1000 (2008).
64. Ueta M, Sotozono C, Inatomi T, Kojima K, Hamuro J, Kinoshita S. Association of Fas Ligand gene polymorphism with Stevens-Johnson syndrome. Br. J. Ophthalmol. 92(7), 989-991 (2008).
65. Nickoloff BJ. Saving the skin from drug-induced detachment. Nat. Med. 14(12), 1311-1313 (2008).
66. Chung WH, Hung SI, Yang JY et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat. Med. 14(12), 1343-1350 (2008).
67. Verneuil L, Ratajczak P, Allabert C et al. Endothelial cell apoptosis in severe drug-induced bullous eruptions. Br. J. Dermatol. 161(6), 1371-1375 (2009).
68. Knowles SR, Shear NH. Recognition and management of severe cutaneous drug reactions. Dermatol. Clin. 25(2), 245-253, VIII (2007).
69. Chan HL. Observations on drug-induced toxic epidermal necrolysis in Singapore. J. Am. Acad. Dermatol. 10(6), 973-978 (1984).
70. Valeyrie-Allanore L, Poulalhon N, Fagot JP et al. Stevens-Johnson syndrome and toxic epidermal necrolysis induced by amifostine during head and neck radiotherapy. Radiother. Oncol. 87(2), 300-303 (2008).
71. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schroder W, Roujeau JC. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch. Dermatol. 138(8), 1019-1024 (2002).
72. Horne NS, Narayan AR, Young RM, Frieri M. Toxic epidermal necrolysis in systemic lupus erythematosus. Autoimmun. Rev. 5(2), 160-164 (2006).
73. Mandelcorn R, Shear NH. Lupus- associated toxic epidermal necrolysis: a novel manifestation of lupus? J. Am. Acad. Dermatol. 48(4), 525-529 (2003).
74. Wanat KA, Anadkat MJ, Klekotka PA. Seasonal variation of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with trimethoprim- sulfamethoxazole. J. Am. Acad. Dermatol. 60(4), 589-594 (2009).
75. Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP) - a clinical reaction pattern. J. Cutan. Pathol. 28(3), 113-119 (2001). (Pubitemid 32112994)
76. Britschgi M, Pichler WJ. Acute generalized exanthematous pustulosis, a clue to neutrophil-mediated inflammatory processes orchestrated by T cells. Curr. Opin. Allergy Clin. Immunol. 2(4), 325-331 (2002).
77. Britschgi M, Steiner UC, Schmid S et al. T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J. Clin. Invest. 107(11), 1433-1441 (2001).
78. Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin. Liver Dis. 6(3), 755-774 (2002).
79. Marzano AV, Vezzoli P, Crosti C. Drug-induced lupus: an update on its dermatologic aspects. Lupus 18(11), 935-940 (2009).
80. Vedove CD, Del GM, Schena D, Girolomoni G. Drug-induced lupus erythematosus. Arch. Dermatol. Res. 301(1), 99-105 (2009).
81. Brockow K, Romano A, Aberer W et al. Skin testing in patients with hypersensitivity reactions to iodinated contrast media - a European multicenter study. Allergy 64(2), 234-241 (2009).
82. Brockow K, Christiansen C, Kanny G et al. Management of hypersensitivity reactions to iodinated contrast media. Allergy 60 (2), 150-158 (2005). (Pubitemid 40187467)
83. Brockow K. Immediate and delayed reactions to radiocontrast media: is there an allergic mechanism? Immunol. Allergy Clin. North Am. 29(3), 453-468 (2009).
84. Szczeklik A, Stevenson DD. Aspirin- induced asthma: advances in pathogenesis, diagnosis, and management. J. Allergy Clin. Immunol. 111(5), 913-921 (2003).
85. Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J. Allergy Clin. Immunol. 118(4), 773-786 (2006).
86. Grattan CE. Aspirin sensitivity and urticaria. Clin. Exp. Dermatol. 28(2), 123-127 (2003).
87. Sczczeklik A. The cyclooxygenase theory of aspirin-induced asthma. Eur. Respir. J. 3, 588-593 (1990).
88. De Weck AL, Sanz ML, Gamboa PM et al. Nonsteroidal anti-inflammatory drug hypersensitivity syndrome. A multicenter study. I. Clinical findings and in vitro diagnosis. J. Investig. Allergol. Clin. Immunol. 19(5), 355-369 (2009).
89. Jenneck C, Juergens U, Buecheler M, Novak N. Pathogenesis, diagnosis, and treatment of aspirin intolerance. Ann. Allergy Asthma Immunol. 99(1), 13-21 (2007).
90. Palikhe NS, Kim SH, Park HS. What do we know about the genetics of aspirin intolerance? J. Clin. Pharm. Ther. 33(5), 465-472 (2008).
91. Himly M, Jahn-Schmid B, Pittertschatscher K et al. IgE-mediated immediate-type hypersensitivity to the pyrazolone drug propyphenazone. J. Allergy Clin. Immunol. 111(4), 882-888 (2003).
92. Kowalski ML, Bienkiewicz B, Woszczek G, Iwaszkiewicz J, Poniatowska M. Diagnosis of pyrazolone drug sensitivity: clinical history versus skin testing and in vitro testing. Allergy Asthma Proc. 20(6), 347-352 (1999).
93. Wedi B, Kapp A. Aspirin induced adverse skin reactions: new pathophysiological aspects. Thorax 55, S70-S71 (2000).
94. Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L et al. EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy 62(10), 1111-1118 (2007).
95. Bousquet PJ, Demoly P, Romano A et al. Pharmacovigilance of drug allergy and hypersensitivity using the ENDA-DAHD database and the GALEN platform. The Galenda project. Allergy 64(2), 194-203 (2009).